E.g., 06/10/2023
E.g., 06/10/2023

2023

Financial Disclosures
07/06/2023
14:40
Communication of total amount of voting rights (7 June 2023)
Other
05/06/2023
21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment.
Acquisition / Partnership
26/05/2023
07:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM
Financial data
09/05/2023
11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023
Other
28/04/2023
12:52
Shareholders' Meeting 2023
Financial Disclosures
27/03/2023
15:52
Update 2023 Annual Calendar of Corporate Events
Financial data
27/03/2023
14:38
Dividend coupon date correction
Financial data
27/03/2023
13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE
Products
17/03/2023
22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance
Acquisition / Partnership
28/02/2023
16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed
Acquisition / Partnership
13/02/2023
22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN
Financial Disclosures
07/02/2023
12:01
Update 2023 Annual Calendar of Corporate Events

2022

Other
01/12/2022
18:30
2023 Annual Calendar of Corporate Events
Products
09/11/2022
07:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance
Products
07/11/2022
07:12
DiaSorin commercializes molecular reagent for monkeypox virus
Financial data
27/10/2022
13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards
Products
05/10/2022
06:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES
Products
14/09/2022
00:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE
Financial data
03/08/2022
12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards
Products
14/07/2022
20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test
Other
07/06/2022
18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin
Products
20/05/2022
07:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay
Acquisition / Partnership
09/05/2022
07:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™
Financial Disclosures
06/05/2022
17:33
Update 2022 Annual Calendar of Corporate Events
Financial data
06/05/2022
16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards
Financial Disclosures
02/05/2022
12:55
Publication of the summary report of the votes cast
Other
29/04/2022
16:26
Shareholders' meeting 2022
Financial Disclosures
22/04/2022
12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors
Financial Disclosures
13/04/2022
16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative
Financial Disclosures
08/04/2022
19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution
Financial Disclosures
08/04/2022
09:53
Update annual calendar of corporate events 2022
Other
05/04/2022
09:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999
Other
04/04/2022
18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l.
Financial data
16/03/2022
17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
Products
08/03/2022
07:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel
Products
13/01/2022
07:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant

2021

Other
21/12/2021
11:07
2022 Annual Calendar of Corporate Events
Financial data
16/12/2021
22:47
DiaSorin 2022-2025 Strategic Plan
Products
30/11/2021
19:10
DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant
Products
29/11/2021
07:06
DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer
Products
23/11/2021
07:10
DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark
Financial data
11/11/2021
16:56
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021
Other
05/11/2021
11:22
Weekly report treasury shares buy-back
Other
02/11/2021
20:00
Conclusion treasury shares buy-back plan
Other
02/11/2021
19:57
Weekly report treasury shares buy-back
Other
27/10/2021
16:35
Issuance of the "Physical Settlement Notice"
Other
07/10/2021
11:45
Publication of the summary report of the votes
Other
04/10/2021
12:27
The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase
Products
18/09/2021
08:16
DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test
Other
30/07/2021
18:43
Start up of the treasury shares buy-back plan
Financial data
30/07/2021
12:57
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex
Other
22/07/2021
18:28
Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999
Acquisition / Partnership
14/07/2021
15:05
DiaSorin announces completion of the Acquisition of Luminex Corporation
Acquisition / Partnership
09/07/2021
07:34
DiaSorin obtains all approvals necessary to complete the acquisition of Luminex
Acquisition / Partnership
21/06/2021
18:49
The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin
Products
15/06/2021
06:56
DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E
Other
07/06/2021
15:16
Communication on total amount of voting rights
Acquisition / Partnership
03/06/2021
07:47
DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ
Products
25/05/2021
07:03
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection
Products
21/05/2021
07:02
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2
Products
20/05/2021
08:27
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market
Financial data
14/05/2021
16:10
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021
Financial data
28/04/2021
17:46
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028
Financial data
28/04/2021
07:54
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028
Other
22/04/2021
15:58
Shareholders' meeting April 22, 2021
Products
21/04/2021
07:02
DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology
Products
20/04/2021
18:58
DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark
Other
14/04/2021
10:05
Communication voting rights amount
Other
12/04/2021
11:08
Weekly report treasury shares buy-back
Acquisition / Partnership
11/04/2021
19:47
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion
Other
06/04/2021
08:53
Start up buy-back plan
Acquisition / Partnership
06/04/2021
07:06
DiaSorin announces its strategic collaboration with Lumos Diagnostics
Products
30/03/2021
07:01
DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test
Products
29/03/2021
07:02
DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S.
Financial data
11/03/2021
16:37
Dividend coupon date correction
Financial data
11/03/2021
15:31
Revenues, Profitability and Cash Flow Generation hit record highs in 2020
Products
23/02/2021
06:11
DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market
Other
27/01/2021
18:50
2021 Annual Calendar of Corporate Events
Products
11/01/2021
18:43
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test

2020

Products
29/12/2020
18:22
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance
Other
07/12/2020
10:35
Communication on total amount of voting rights
Other
04/12/2020
16:14
Form 3F (November 2020)
Products
01/12/2020
06:33
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market
Financial data
11/11/2020
12:41
North America growth drives up revenues and profitability in the first 9 months of 2020
Products
26/10/2020
18:30
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients
Other
23/10/2020
19:41
Conclusion treasury shares buy-back plan
Other
23/10/2020
19:37
Weekly report treasury shares buy-back
Other
16/10/2020
18:28
Weekly report treasury shares buy-back
Products
01/10/2020
07:45
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market
Products
01/10/2020
07:32
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market
Acquisition / Partnership
23/09/2020
07:16
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China
Other
16/09/2020
14:30
Update Annual Calendar of Corporate Events 2020
Products
16/09/2020
07:25
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens
Acquisition / Partnership
08/09/2020
07:31
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
Products
07/09/2020
18:22
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay
Products
06/08/2020
07:25
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone
Other
31/07/2020
16:04
Weekly report treasury shares buy-back
Financial data
30/07/2020
13:16
North America business growth drives Group revenues and profitability in H1 2020
Other
24/07/2020
17:19
Weekly report treasury shares buy-back
Other
17/07/2020
18:19
Weekly report treasury shares buy-back
Other
10/07/2020
18:23
Weekly report treasury shares buy-back
Products
09/07/2020
07:27
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study
Products
07/07/2020
07:22
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay
Products
30/06/2020
07:25
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients
Other
19/06/2020
17:20
Weekly report treasury shares buy-back
Other
17/06/2020
16:09
Start up of the treasury shares buy-back plan
Products
12/06/2020
07:30
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay
Other
10/06/2020
15:40
Shareholders' Meeting June 10, 2020
Products
03/06/2020
14:16
The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA
02/06/2020
14:58
Communication total amount voting rights (record date)
Products
18/05/2020
11:28
The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada
Financial data
13/05/2020
13:15
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic
Products
25/04/2020
16:49
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG
Products
17/04/2020
18:25
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19
Products
07/04/2020
07:14
IgG test to detect immune response to SARS-CoV-2
Other
26/03/2020
18:14
Update Annual Calendar of Corporate Events 2020
Other
21/03/2020
20:29
Shareholders' Meeting date change
Products
20/03/2020
07:28
DiaSorin COVID-19 test has received FDA Emergency Use Authorization
Products
13/03/2020
17:16
DiaSorin received BARDA funding to develop a rapid COVID-19 test
Financial data
11/03/2020
13:43
DiaSorin - Cash flow generation and net profit hit record highs in 2019
Products
10/03/2020
08:20
DiaSorin - Development of Coronavirus test
Acquisition / Partnership
02/03/2020
08:04
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology
Other
07/02/2020
08:06
Communication on total amount of voting rights
Other
15/01/2020
16:51
Annual Calendar of Corporate Events 2020

2019

Products
16/12/2019
14:10
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay
Other
06/12/2019
18:12
Press Release
Other
06/12/2019
18:11
Press Release
Other
06/12/2019
18:08
Communication on total amount of voting rights
Products
27/11/2019
07:59
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET
Products
11/11/2019
09:46
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET
Financial data
06/11/2019
13:00
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019
Products
30/10/2019
09:55
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET
Products
22/10/2019
14:10
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET
Other
07/10/2019
10:20
Communication on total amount of voting rights
Products
24/09/2019
10:10
DiaSorin launches VZV Direct molecular test in Europe
Financial data
31/07/2019
13:00
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.
Financial data
10/06/2019
18:23
DiaSorin presents its 2019-2022 Industrial Plan
Acquisition / Partnership
05/06/2019
07:38
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease
Products
29/05/2019
15:06
DiaSorin launches VZV DIRECT molecular test in the United States
Financial data
09/05/2019
13:14
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019
Products
06/05/2019
15:19
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL
Other
30/04/2019
12:28
Update Annual Calendar of Corporate Events 2019
Other
24/04/2019
17:24
DiaSorin: Shareholders' Meeting 2019
Other
12/04/2019
08:59
Communication on total amount of voting rights
Other
05/04/2019
09:33
Communication on total amount of voting rights
Other
03/04/2019
20:18
Lists publication
Products
03/04/2019
10:32
DiaSorin launches the anaemia panel on Liaison XL in Europe
Financial data
14/03/2019
14:16
Growth in revenues, profitability and net profit in 2018
Other
07/03/2019
11:45
Communication on total amount of voting rights
Other
06/03/2019
08:45
A new Group website for DiaSorin: www.diasoringroup.com
Other
07/02/2019
15:15
Communication on total amount of voting rights (February 7, 2019)
Products
31/01/2019
22:30
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market
Products
03/01/2019
13:30
DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States

2018

Products
21/12/2018
11:30
DiaSorin launches 3 new primer pairs for use in molecular testing
Financial data
04/12/2018
08:00
DiaSorin's stocks listed in the FTSE MIB
Products
19/11/2018
15:00
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States
Financial data
07/11/2018
13:00
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018
Products
17/10/2018
11:51
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market
Products
12/10/2018
11:47
DiaSorin launches Simplexa VZV Direct molecular assay in the european market
Acquisition / Partnership
09/10/2018
11:35
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom
Products
17/09/2018
11:28
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen
Financial data
07/08/2018
08:45
Communication on total amount of voting rights
Financial data
02/08/2018
12:45
The Board of Directors approves the results for the first half of 2018
Products
27/07/2018
12:00
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform
Financial data
03/07/2018
18:30
Report treasury shares buy-back
Financial data
03/07/2018
18:30
Annex 3F (treasury shares buy back July 2018)
Financial data
03/07/2018
18:30
Conclusion treasury shares buy-back plan
Financial data
03/07/2018
18:30
Annex 3F (treasury shares buy back June 2018)
Financial data
29/06/2018
18:15
Weekly report treasury shares buy-back
Financial data
22/06/2018
20:30
Weekly report treasury shares buy-back
Financial data
15/06/2018
21:00
Weekly report treasury shares buy-back
Products
12/06/2018
14:15
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia
Financial data
08/06/2018
23:15
Weekly report treasury shares buy-back
Financial data
04/06/2018
13:15
Annex 3F (treasury shares buy back May 2018)
Financial data
01/06/2018
20:15
Weekly report treasury shares buy-back
Financial data
25/05/2018
22:30
Weekly report treasury shares buy-back
Financial data
19/05/2018
01:45
Weekly report treasury shares buy-back
Financial data
11/05/2018
20:15
Weekly report treasury shares buy-back
Financial data
08/05/2018
14:30
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018
Financial data
03/05/2018
20:15
Start up treasury shares buy-back plan
Financial data
24/04/2018
14:00
Annex 3F (treasury shares buy back)
Financial data
23/04/2018
18:30
Annual General Meeting 2018
Financial data
19/04/2018
21:15
Conclusion treasury shares buy-back plan
Financial data
19/04/2018
21:00
Weekly report treasury shares buy-back
Financial data
13/04/2018
20:30
Weekly report treasury shares buy-back
Financial data
06/04/2018
19:45
Weekly report treasury shares buy-back
Products
05/04/2018
12:00
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis)
Financial data
04/04/2018
20:00
Start up treasury shares buy-back plan
Products
28/03/2018
18:45
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test
Financial data
07/03/2018
15:30
DiaSorin: FY 2017 Results
Financial data
30/01/2018
11:45
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime
Acquisition / Partnership
08/01/2018
09:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems
Acquisition / Partnership
08/01/2018
09:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems

2017

Products
12/12/2017
13:15
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test
Other
29/11/2017
19:30
Resignation of a Strategic Executive of the Company
Financial data
09/11/2017
14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED
Financial data
29/09/2017
15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS
Acquisition / Partnership
29/09/2017
14:15
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
Products
21/09/2017
12:45
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit
Financial data
03/08/2017
14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017
Products
28/07/2017
14:45
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS
Acquisition / Partnership
25/07/2017
21:00
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS
Products
10/07/2017
13:30
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP
Financial data
26/06/2017
09:45
DiaSorin presents its 2017-2019 Industrial Plan
Acquisition / Partnership
23/06/2017
09:30
DiaSorin and TECAN to collaborate in new platform development
Acquisition / Partnership
22/06/2017
19:45
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays
Products
23/05/2017
11:45
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders
Products
16/05/2017
13:00
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality
Financial data
08/05/2017
19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow
Financial data
27/04/2017
18:45
DiaSorin - Annual General Meeting 2016
Products
21/04/2017
18:45
DiaSorin receives authorization for the distribution of Zika IgM test in Europe
Products
06/04/2017
18:00
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test
Financial data
08/03/2017
15:30
The Board of Directors approves the results for FY'16
Products
21/02/2017
11:30
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market
Products
26/01/2017
12:45
DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE

2016

Financial data
19/12/2016
10:00
Co-optation of a Director
Financial data
10/11/2016
01:00
DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016
Products
02/11/2016
01:00
DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST
Acquisition / Partnership
30/08/2016
02:00
DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market
Products
22/08/2016
02:00
DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY
Financial data
04/08/2016
02:00
The Board of Directors approves results for H1'16
Products
28/07/2016
02:00
DiaSorin starts selling Vitamin D in Japan
Products
14/07/2016
02:00
DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia
Financial data
10/06/2016
02:00
Conclusion buy-back plan
Financial data
10/06/2016
02:00
Weekly report treasury shares buy-back
Products
07/06/2016
02:00
DiaSorin launches the new Helicobacter pylori IgG CLIA test
Financial data
03/06/2016
02:00
Weekly report treasury shares buy-back
Financial data
30/05/2016
02:00
Notice filing By-Laws and publication operating procedures for loyalty shares
Financial data
27/05/2016
02:00
Weekly report treasury shares buy-back
Financial data
20/05/2016
02:00
Weekly report treasury shares buy-back
Acquisition / Partnership
13/05/2016
02:00
Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business
Financial data
12/05/2016
02:00
Start up treasury shares buy-back plan
Financial data
09/05/2016
02:00
The Board of Directors approves the results for Q1'16
Financial data
28/04/2016
02:00
Shareholders' Meeting FY 2015
Acquisition / Partnership
30/03/2016
02:00
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business
Financial data
09/03/2016
01:00
The Board of Directors approves the results for FY'15

2015

Financial data
11/11/2015
01:00
The Board of Directors approves the results for Q3'15
Products
09/09/2015
02:00
DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias
Financial data
30/07/2015
02:00
H1'15 Results
Acquisition / Partnership
20/07/2015
02:00
DiaSorin and Beckman Coulter sign a distribution agreement for China
Products
28/05/2015
02:00
DiaSorin launches the test for Campylobacter
Other
12/05/2015
02:00
DiaSorin presents the 2015-2017 industrial plan
Financial data
12/05/2015
02:00
The Board of Directors approves the results for Q1'15
Products
29/04/2015
02:00
DiaSorin - launches the test for Brahms-Sepsis
23/04/2015
02:00
DiaSorin supports the Pinocchio Project
Financial data
22/04/2015
02:00
The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day
Financial data
22/04/2015
02:00
Shareholders' meeting approves FY Results 2014
Products
14/04/2015
02:00
DiaSorin launches the tests for Bordetella pertussis
Financial data
10/04/2015
02:00
Investor Day-save the date
24/03/2015
01:00
DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation
Financial data
03/03/2015
01:00
The Board of Directors approves the results for FY'14
24/02/2015
01:00
DiaSorin supports Emergency in Sudan
13/02/2015
01:00
DiaSorin teams with FISIP for Progetto talenti
Products
14/01/2015
01:00
DiaSorin launches the test for Calprotectin

2014

Products
16/12/2014
01:00
FDA approves 1,25 Vitamin D in the US market
Products
09/12/2014
01:00
DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL
Financial data
14/11/2014
01:00
The Board of Directors approves the results for Q3'14
Products
07/10/2014
02:00
DiaSorin launches the test for HIV HT on LIAISON
Products
18/09/2014
02:00
DiaSorin launches the stool test for Adenovirus on LIAISON
Financial data
01/08/2014
02:00
The Board of Directors approves the results for H1'14
Financial data
22/07/2014
02:00
DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME
Products
30/06/2014
02:00
DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM
Products
03/06/2014
02:00
DiaSorin launches the test for Vitamin D 1,25 on LIAISON
Financial data
09/05/2014
02:00
The Board of Directors approves the results for Q1'14
Financial data
23/04/2014
02:00
Shareholders' meeting approves FY Results 2013
Financial data
06/03/2014
01:00
The Board of Directors approves the results for FY'13
Products
18/02/2014
01:00
DiaSorin launches the new test for PTH on LIAISON
Products
11/02/2014
01:00
DiaSorin launches the test for Rotavirus on stool sample
Acquisition / Partnership
28/01/2014
01:00
DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018
Products
24/01/2014
01:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China
Products
09/01/2014
01:00
DiaSorin launches the test for Cytomegalovirus on LIAISON IAM

2013

Financial data
08/11/2013
01:00
The Board of Directors approves the Q3'13 Results
Acquisition / Partnership
29/10/2013
01:00
DiaSorin signes a 5-year agreement with Roche
Products
25/10/2013
02:00
DiaSorin launches the EHEC Toxins test on stool samples
Products
10/10/2013
02:00
DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas)
Products
24/09/2013
02:00
DiaSorin launches the hCG test on its LIAISON XL in the US
Financial data
01/08/2013
02:00
The Board of Directors approves the results for the H1 '13
Products
24/07/2013
02:00
DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM
Products
11/07/2013
02:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil
Products
28/06/2013
02:00
DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON
Products
20/06/2013
02:00
DiaSorin launches the new test for Parvovirus on LIAISON IAM
Financial data
10/05/2013
02:00
The Board of Directors approves the results for Q1'13
Financial data
02/05/2013
02:00
Compensation Commitee-Errata corrige
Financial data
22/04/2013
02:00
Shareholders' meeting approves FY Results 2012
Products
17/04/2013
02:00
FDA approves the Aldosterone assay
Acquisition / Partnership
02/04/2013
02:00
DiaSorin signs an agreement with Seegene
Financial data
08/03/2013
01:00
The BoD approves FY 2012 results
Financial data
07/03/2013
01:00
Notice availability By-Laws
Financial data
07/03/2013
01:00
Notification of changes in share capital
Financial data
07/02/2013
01:00
Notice availability By-Laws
Financial data
07/02/2013
01:00
Notification of changes in share capital
Products
07/02/2013
01:00
Clostridium difficile on LIAISON (available outside the US and Canada only)
Financial data
30/01/2013
01:00
The Board of Directors approves the results for the FY '12
Products
29/01/2013
01:00
Aldosterone on LIAISON (available outside the US and Canada only)

2012

Financial data
20/12/2012
01:00
Shareholders' meeting
Financial data
07/11/2012
01:00
The BoD approves Q3'12 results
Financial data
03/08/2012
02:00
The BoD approves H1'12 results
Acquisition / Partnership
30/07/2012
02:00
DiaSorin in India: JV with Trivitron Healthcare
Financial data
27/06/2012
02:00
Notification of changes in share capital
Financial data
11/05/2012
02:00
The BoD approves Q1'12 results
Acquisition / Partnership
04/05/2012
02:00
NorDiag acquisition
Financial data
23/04/2012
02:00
2011 statutory financial statement approval
Products
10/04/2012
02:00
Measles and Mumps IgM on LIAISON (available outside the US and Canada only)
Products
02/04/2012
02:00
Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only)
Financial data
30/03/2012
02:00
Financial calendar update
Financial data
22/03/2012
01:00
Stock options to employees
Acquisition / Partnership
12/03/2012
01:00
Agreement with Sonic Healthcare on Vitamin D
Financial data
09/03/2012
01:00
The BoD approves FY 2011 results
Financial data
07/03/2012
01:00
Notification of changes in share capital
Acquisition / Partnership
17/02/2012
01:00
DiaSorin became a member of the ISBT
Financial data
09/02/2012
01:00
Notice of change in share capital
Products
02/02/2012
01:00
FDA clearance for 25 OH Vitamin D on LIAISON
Financial data
27/01/2012
01:00
2012 Financial calendar update
Financial data
25/01/2012
01:00
Dividend distribution in June
Other
19/01/2012
01:00
Prize for best Italian Company in R&D in the UK
Financial data
13/01/2012
01:00
2012 Financial calendar
Products
12/01/2012
01:00
New anti HBs II (available outside the US and Canada only)

2011

Financial data
23/12/2011
01:00
Financial instruments to employees
Products
19/12/2011
01:00
Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only)
Financial data
19/11/2011
01:00
Buy-back plan
Financial data
18/11/2011
01:00
Financial instruments to employees
Financial data
11/11/2011
01:00
The BoD approves Q3'11 results
Financial data
28/10/2011
02:00
Buy-back plan
Financial data
25/10/2011
02:00
Buy-back plan
Financial data
18/10/2011
02:00
Buy-back plan
Financial data
17/10/2011
02:00
2011-2015 Business Plan: a new business wave
Other
10/10/2011
02:00
New Chief Financial Officer
Acquisition / Partnership
06/10/2011
02:00
Cardinal Health: agreement extended to 2014
Financial data
04/10/2011
02:00
Buy-back plan
Other
01/09/2011
02:00
Resignation of Chief Financial Officer
Financial data
31/08/2011
02:00
2011 Financial calendar update
Financial data
03/08/2011
02:00
The BoD approves H1'11 results
Financial data
11/07/2011
02:00
Voluntarily removal from the STAR segment
Financial data
13/05/2011
02:00
The BoD approves Q1'11 results
Acquisition / Partnership
11/05/2011
02:00
DiaSorin and Labcorp extend strategic business relationship
Acquisition / Partnership
06/05/2011
02:00
Agreement with Precision System Science Co., LTD
Financial data
28/04/2011
02:00
The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution
Financial data
16/03/2011
01:00
Dividend information amendment
Financial data
16/03/2011
01:00
The BoD approves FY'10 results
Financial data
28/02/2011
01:00
2011 Financial calendar update
Financial data
19/02/2011
01:00
Notice of change in share capital
Financial data
18/02/2011
01:00
Buy-back plan
Financial data
17/02/2011
01:00
Financial instruments to employees
Financial data
16/02/2011
01:00
Buy-back plan
Financial data
15/02/2011
01:00
Buy-back plan
Financial data
14/02/2011
01:00
The BoD approves Q4'10 results
Financial data
31/01/2011
01:00
Buy-back plan
Financial data
29/01/2011
01:00
Buy-back plan
Financial data
28/01/2011
01:00
Buy-back plan
Financial data
27/01/2011
01:00
Buy-back plan
Products
26/01/2011
01:00
FDA approves the LIAISON XL
Financial data
25/01/2011
01:00
Buy-back plan
Financial data
24/01/2011
01:00
Buy-back plan
Financial data
21/01/2011
01:00
Buy-back plan
Financial data
20/01/2011
01:00
Buy-back plan
Financial data
19/01/2011
01:00
Buy-back plan
Financial data
18/01/2011
01:00
Buy-back plan
Financial data
17/01/2011
01:00
Buy-back plan
Acquisition / Partnership
17/01/2011
01:00
The Sonic Healthcare Group chooses DiaSorin
Financial data
16/01/2011
01:00
2011 Financial calendar

2010

Financial data
22/12/2010
01:00
2011 Financial calendar
Financial data
20/12/2010
01:00
Dividend may be distributed in June
Products
02/12/2010
01:00
Comment on position Paper on Vitamin D
Financial data
24/11/2010
01:00
Change in share capital
Financial data
18/11/2010
01:00
Financial instruments to employees
Financial data
05/11/2010
01:00
The BoD approves Q3'10 results
Financial data
02/11/2010
01:00
Change in share capital
Financial data
08/10/2010
02:00
2010 Financial calendar update
Financial data
30/09/2010
02:00
Change in share capital
Financial data
24/09/2010
02:00
Financial instruments to employees
Financial data
16/09/2010
02:00
Stock options exercised by key managers
Financial data
02/09/2010
02:00
Financial instruments to employees
Financial data
06/08/2010
02:00
The BoD approves H1'10 results
Acquisition / Partnership
07/07/2010
02:00
Agreement with Meridian Inc.
Financial data
06/07/2010
02:00
2010 Financial calendar update
Financial data
02/07/2010
02:00
Financial instruments to employees
Acquisition / Partnership
01/06/2010
02:00
Acquisition of MUREX product line
Financial data
14/05/2010
02:00
The BoD approves Q1'10 results
Financial data
27/04/2010
02:00
Approval of statutory financial statements
Financial data
20/04/2010
02:00
2010 Financial calendar update
Financial data
14/04/2010
02:00
Postponement of the term for lists of members of the Board of Auditors
Products
09/04/2010
02:00
China approves new prenatal screening product line on LIAISON
Financial data
02/04/2010
02:00
Financial instruments to employees
Financial data
22/03/2010
01:00
The BoD approves FY 2009 results
Acquisition / Partnership
10/03/2010
01:00
Acquisition of MUREX product line
Financial data
01/03/2010
01:00
2010 Financial calendar update
Financial data
12/02/2010
01:00
The BoD approves Q4'09 results
Financial data
18/01/2010
01:00
2010 Financial calendar

2009

Financial data
24/12/2009
01:00
Financial instruments to employees
Financial data
30/10/2009
01:00
The BoD approves Q3'09 results
Other
12/10/2009
02:00
Strengthening of group's R&D team
Financial data
08/10/2009
02:00
2009 Financial calendar update
Financial data
05/10/2009
02:00
Financial instruments to employees
Financial data
06/08/2009
02:00
The BoD approves H1'09 results
Financial data
08/06/2009
02:00
2009 Financial calendar update
Financial data
18/05/2009
02:00
Financial instruments to employees
Financial data
10/04/2009
02:00
Corporate Governance Report at December 2008.
Financial data
08/04/2009
02:00
2009 Financial calendar update
Financial data
19/03/2009
01:00
The BoD approves FY 2008 results
Financial data
20/02/2009
01:00
Financial instruments to employees
Financial data
13/02/2009
01:00
The BoD approves Q4'08 results
Financial data
28/01/2009
01:00
2009 Financial calendar
Products
08/01/2009
01:00
FDA clearance to five LIAISON products

2008

Financial data
23/12/2008
01:00
Financial instruments to employees
Financial data
21/11/2008
01:00
Financial instruments to employees
Financial data
13/11/2008
01:00
The BoD approves Q3'08 results
Acquisition / Partnership
22/09/2008
02:00
Agreement in Japan with Advanced Life Science Institute
Financial data
08/08/2008
02:00
The BoD approves H1'08 results
Acquisition / Partnership
09/07/2008
02:00
Acquisition of Biotrin
Financial data
16/05/2008
02:00
Financial instruments to employees
Financial data
15/05/2008
02:00
Results for Q1'08
Financial data
24/04/2008
02:00
2007 statutory financial Statements approved
Financial data
21/04/2008
02:00
2008 Financial calendar update
Financial data
19/03/2008
01:00
The BoD approves FY 2007 results
Financial data
14/02/2008
01:00
The BoD approves Q4'07 results
Financial data
29/01/2008
01:00
2008 Financial calendar
Financial data
07/01/2008
01:00
Financial instruments to employees

eMarket SDIR System and eMarket STORAGE

For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.com), managed by Spafid Connect S.p.A., with registered office in Foro Bonaparte, 10, Milan, Italy.